Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Internal Medicine Physician in San Francisco, CA
NPI: 1154684777Primary Practice Location
UCSF MEDICAL CENTER
1975 4th St, San Francisco, CA
Primary Employer
UCSF Medical Center
ucsfhealth.org
HQ Phone
Get M.D. Vadim's Phone NumberMobile
Get M.D. Vadim's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMI State Medical License
OH State Medical License
CA State Medical License
2018 - 2027
OH State Medical License
2015 - 2018
MI State Medical License
2012 - 2015
American Board of Internal Medicine
Internal Medicine
American Board of Internal Medicine
Medical Oncology
Pritzker School of Medicine
pritzker.uchicago.edu
Medical School
Until 2012
Cleveland Clinic Foundation
Fellowship • Hematology and Medical Oncology
2015 - 2018
University of Michigan
Residency • Internal Medicine
2012 - 2015
University of Pennsylvania
BA • Cognitive Science
2003 - 2007
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 179 | 493 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 39 | 39 |
| 3 | 36415Insertion of needle into vein for collection of blood sample | 14 | 47 |
Authors: Rohit Bose, David Oh, Jonathan Chou, Terence Friedlander, Eric Small, Rahul Aggarwal, Arpita Desai, Thomas Hope
Journal: Lancet Oncol
Authors: Carissa Chu, Maxwell Meng, Peter Black, Emily Chan, Jonathan Chou, Sima Porten, Terence Friedlander, Emily Chan, Raj Pruthi
Journal: Eur Urol Oncol
Publication Date: 2022-02-23
Authors: Mehmet Bilen, Arjun Balar, Maged Khalil, Mary Tagliaferri, Arlene Siefker-Radtke, David Chien
Journal: Future Oncol
Publication Date: 2020-09-17
Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Collaborators: Merck Sharp & Dohme LLC, RemeGen Co., Ltd.
Intervention / Treatment: DRUG: carboplatin, DRUG: cisplatin, DRUG: pembrolizumab, DRUG: gemcitabine, DRUG: disitamab vedotin
Lead Sponsor: Merck Sharp & Dohme LLC
Intervention / Treatment: BIOLOGICAL: Pembrolizumab, COMBINATION_PRODUCT: EV, BIOLOGICAL: Coformulated favezelimab/pembrolizumab, BIOLOGICAL: Coformulated vibostolimab/pembrolizumab
Lead Sponsor: Vadim S Koshkin
Collaborators: Eli Lilly and Company, Prostate Cancer Foundation
Intervention / Treatment: DRUG: Abemaciclib, DRUG: Lutetium Lu 177-PSMA-617
